Anti-body Coupled T Receptor Therapy Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-202

1. Anti-body Coupled T Receptor Therapy Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026 Anti-Body Coupled T Receptor Therapy Market – Global Industry Insights, Trends, Trends, Outlook and Opportunity Analysis 2018-2026 Anti-Body Coupled T Receptor Therapy Market Download PDF Brochure of Market Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1600 Anti-body coupled T receptor (ACTR) therapy is kind of immunotherapy used to treat cancer in which body’s own immune response is utilized to act on cancerous cell. Anti-body coupled T receptor therapy utilizes T cells from body, engineered it to express specifc T cell receptor, multiplying it in lab and then administering it along with targeting antibodies. The advantage in this approach is, that these T cells do not attack normal antigens from blood circulation but attack only antigens attached to the cancerous cells. This is possible as tumor specifc monoclonal antibodies are given together with ACTR T cells. ACTR therapy is cost efective as it can be used in various cancer therapy. Also, greater therapeutic beneft with minimum side efects can be possible by aduusting the amount of targeting antibody which is essential for activation of the ACTR T cells. Rising incidence of cancer and new products to be launched in future to drive the market for anti-body coupled T receptor therapy market. According to World Health Organization (WHO), cancer is one of the leading non-communicable disease and second leading cause of death globally. As reported by International Agency for Research on Cancer (IARC) in 2012, there were 14.1 million new cases, 8.8 million deaths and 32.6 million people living with cancer worldwide. As per 2017 report by Leukemia and Lymphoma

2. Society, U.S. alone is expected to have prevalence of 8,16,834 and 80,500 annual new cases of lymphoma. Therefore, such high number of cancer patient would propel the anti-body coupled T receptor therapy market. ACTR therapy is better in its approach than other adoptive T cell transfer technologies such as CAR-T cell therapy. CAR-T therapy products such as Kymriah (Novartis AG) or Yescarta (Gilead Lifescience, Inc.) has side efects such as cytokine release syndrome, and neurological toxicity as discussed in their respective product literatures and other studies. ACTR therapy being specifc in its action do not produce such side efects. This advantage would drive the anti-body coupled T receptor therapy market in future. Also CAR-T therapy has application in specifc type of cancer such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, multiple myeloma whereas ACTR therapy has potential use even in solid tumorous cancer such as breast cancer, and neuroblastoma. Cost of product can be a mauor concern. Kymriah which is a CAR-T therapy costs approximately US$ 4,75,000 per patient. Considering such high cost for CAR-T therapy it can be assumed that anti-body coupled T receptor therapy can also costs on similar line as it works in same segment of immuno oncology, which may limit the potential growth of anti-body coupled T receptor therapy market. Browse more about the Deep Brain Stimulation Devices Market Study: https://www.coherentmarketinsights.com/insight/request-customization/1600 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com